BR112016002319A2 - constructo de expressão, polinucleotídio, vetor de clonagem ou vetor de expressão, célula hospedeira, método para produzir um polipeptídeo, método para produzir um anticorpo biespecífico, método para otimizar o nível de expressão de uma proteína de interesse e método para otimizar o nível de hetero-dimerização de uma proteína de interesse - Google Patents

constructo de expressão, polinucleotídio, vetor de clonagem ou vetor de expressão, célula hospedeira, método para produzir um polipeptídeo, método para produzir um anticorpo biespecífico, método para otimizar o nível de expressão de uma proteína de interesse e método para otimizar o nível de hetero-dimerização de uma proteína de interesse

Info

Publication number
BR112016002319A2
BR112016002319A2 BR112016002319A BR112016002319A BR112016002319A2 BR 112016002319 A2 BR112016002319 A2 BR 112016002319A2 BR 112016002319 A BR112016002319 A BR 112016002319A BR 112016002319 A BR112016002319 A BR 112016002319A BR 112016002319 A2 BR112016002319 A2 BR 112016002319A2
Authority
BR
Brazil
Prior art keywords
optimizing
interest
protein
expression
level
Prior art date
Application number
BR112016002319A
Other languages
English (en)
Inventor
Aebischer-Gumy Christel
Bertschinger Martin
Moretti Pierre
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of BR112016002319A2 publication Critical patent/BR112016002319A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR112016002319A 2013-08-06 2014-08-05 constructo de expressão, polinucleotídio, vetor de clonagem ou vetor de expressão, célula hospedeira, método para produzir um polipeptídeo, método para produzir um anticorpo biespecífico, método para otimizar o nível de expressão de uma proteína de interesse e método para otimizar o nível de hetero-dimerização de uma proteína de interesse BR112016002319A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13179375 2013-08-06
PCT/EP2014/066826 WO2015018832A1 (en) 2013-08-06 2014-08-05 Expression constructs and methods for expressing polypeptides in eukaryotic cells

Publications (1)

Publication Number Publication Date
BR112016002319A2 true BR112016002319A2 (pt) 2017-09-12

Family

ID=51300736

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002319A BR112016002319A2 (pt) 2013-08-06 2014-08-05 constructo de expressão, polinucleotídio, vetor de clonagem ou vetor de expressão, célula hospedeira, método para produzir um polipeptídeo, método para produzir um anticorpo biespecífico, método para otimizar o nível de expressão de uma proteína de interesse e método para otimizar o nível de hetero-dimerização de uma proteína de interesse

Country Status (14)

Country Link
US (3) US20150056655A1 (pt)
EP (1) EP3030579A1 (pt)
JP (3) JP2016528896A (pt)
KR (2) KR20200044154A (pt)
CN (1) CN105658665A (pt)
AU (2) AU2014304570B2 (pt)
BR (1) BR112016002319A2 (pt)
CA (1) CA2920574C (pt)
EA (1) EA201690271A1 (pt)
IL (2) IL243967A0 (pt)
MX (1) MX2016001678A (pt)
NZ (1) NZ717178A (pt)
SG (1) SG11201600736SA (pt)
WO (1) WO2015018832A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4223784A3 (en) * 2015-09-02 2023-10-04 The Regents of the University of Colorado, a body corporate Compositions and methods for modulating t-cell mediated immune response
WO2020205604A1 (en) * 2019-03-29 2020-10-08 Salk Institute For Biological Studies High-efficiency reconstitution of rna molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136566A (en) * 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US20040072243A1 (en) * 1996-10-11 2004-04-15 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
KR20070004026A (ko) * 2004-03-15 2007-01-05 비오겐 아이덱 엠에이 아이엔씨. 선택적 스플라이싱을 이용하여 진핵 세포에서 폴리펩티드다량체를 발현하기 위한 방법 및 구축물
WO2007135515A1 (en) * 2006-05-16 2007-11-29 Millegen Method for expressing polypeptides in eukaryotic cells using alternative splicing
US9273364B2 (en) * 2010-06-01 2016-03-01 Kyoto University Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms

Also Published As

Publication number Publication date
CN105658665A (zh) 2016-06-08
US20200172634A1 (en) 2020-06-04
KR20160035084A (ko) 2016-03-30
IL269252A (en) 2019-11-28
IL243967A0 (en) 2016-04-21
WO2015018832A1 (en) 2015-02-12
CA2920574C (en) 2021-03-16
CA2920574A1 (en) 2015-02-12
AU2019236586A1 (en) 2019-10-10
US20150056655A1 (en) 2015-02-26
AU2014304570A1 (en) 2016-03-10
EA201690271A1 (ru) 2016-07-29
JP2016528896A (ja) 2016-09-23
MX2016001678A (es) 2016-10-28
NZ717178A (en) 2022-02-25
EP3030579A1 (en) 2016-06-15
KR102104581B1 (ko) 2020-06-02
AU2014304570B2 (en) 2019-07-25
JP2020202840A (ja) 2020-12-24
KR20200044154A (ko) 2020-04-28
JP2022177131A (ja) 2022-11-30
US20170253671A1 (en) 2017-09-07
SG11201600736SA (en) 2016-02-26
AU2019236586B2 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
DK3332006T3 (da) Hidtil ukendte anti-PD-L1-antistoffer
DK3708668T3 (da) Kunstigt nukleinsyremolekyle til forbedret proteinudtrykkelse
DK3411404T3 (da) Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
HK1245813A1 (zh) 抗-cgrp抗體製劑
DK3161007T3 (da) Multispecifikke antistofkonstrukter
DK3356411T3 (da) Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
EP3096609A4 (en) High-throughput mouse model for optimizing antibody affinities
DK3016681T5 (da) Humaniserede eller kimære CD3-antistoffer
BR112017001385A2 (pt) anticorpos anti-pd-1
DK3140393T3 (da) Fremstillingsmetode for voksne leverstamceller
KR20180085002A (ko) 인간화된 항-cll-1 항체
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
DK3237432T3 (da) Proteinfremstilling
DK3334457T3 (da) Humaniserede anti-CCR7-receptorantistoffer
DK3527667T3 (da) Gærpromotorer til proteinekspression
DK3262168T3 (da) Værtscelleproteinmodifikation
SG11201708151TA (en) Method of monomerisation of recombinant antibody molecules
DK3127917T3 (da) Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof
DK3116908T3 (da) Humaniserede kir3dl2-antistoffer
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3
DK3138903T3 (da) Celler til produktion af humant antistof
EP3330376A4 (en) ANTI-EVA 1 PROTEIN ANTIBODY
EP3078674A4 (en) Anti-vegf antibody
IL253932A0 (en) A method for obtaining cell clones with high yield and stable expression, and antibody molecules produced from them.
DK3003385T3 (da) Antistofsammensætning og buffersystem til denne

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ICHNOS SCIENCES SA (CH)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.